Matches in SemOpenAlex for { <https://semopenalex.org/work/W4300644930> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4300644930 endingPage "1429" @default.
- W4300644930 startingPage "1429" @default.
- W4300644930 abstract "<h3>Background:</h3> Several lines of evidence suggest that supplementation of diet with omega-3 polyunsaturated fatty acids (ω-3) PUFA), commonly referred to as fish oils, may reduce blood pressure (BP). However, most clinical trials of ω-3 PUFA supplementation have been of insufficient size to detect relevant BP changes. <h3>Methods:</h3> We conducted a meta-analysis of 17 controlled clinical trials of ω-3 PUFA supplementation. To estimate an overall effect of ω-3 PUFA supplementation on BP, we calculated the net BP change in each trial (BP A in ω-3 PUFA group minus BP A in control group), which was then weighted according to the inverse of the variance. <h3>Results:</h3> In the 11 trials that enrolled normotensive individuals (n=728), ω-3 PUFA supplementation led to significant reductions of systolic BP (SBP) and diastolic BP (DBP) in two and one trials, respectively. In the six studies that enrolled untreated hypertensives (n=291), significant reductions of SBP and DBP were present in two and four trials, respectively. Weighted, pooled estimates of SBP and DBP change (mm Hg) with 95% confidence intervals were —1.0 (—2.0 to 0.0) and —0.5 (—1.2 to +0.2) in the trials of normotensives, and —5.5 (—8.1 to —2.9) and —3.5 (—5.0 to —2.1) in the trials of untreated hypertensives. In 13 of 17 studies, trial duration was less than 3 months. Doses of ω-3 PUFA tended to be high (average dose >3 g/d in 11 trials). The magnitude of BP reduction was greatest at high BP but was not significantly associated with dose of ω-3 PUFA. Side effects, most commonly eructation and a fishy taste, occurred more frequently in ω-3 PUFA participants than in control participants (28% vs 13%,<i>P</i><.001). <h3>Conclusions:</h3> Our analyses indicate that diet supplementation with a relatively high dose of ω-3 PUFA, generally more than 3 g/d, can lead to clinically relevant BP reductions in individuals with untreated hypertension. However, use of ω-3 PUFA as antihypertensive therapy will require demonstration of long-term efficacy and patient acceptability of lower doses. (Arch Intern Med. 1993;153:1429-1438)" @default.
- W4300644930 created "2022-10-03" @default.
- W4300644930 creator A5048680434 @default.
- W4300644930 date "1993-06-28" @default.
- W4300644930 modified "2023-10-17" @default.
- W4300644930 title "Does Supplementation of Diet With 'Fish Oil' Reduce Blood Pressure?" @default.
- W4300644930 doi "https://doi.org/10.1001/archinte.1993.00410120017003" @default.
- W4300644930 hasPublicationYear "1993" @default.
- W4300644930 type Work @default.
- W4300644930 citedByCount "237" @default.
- W4300644930 countsByYear W43006449302012 @default.
- W4300644930 countsByYear W43006449302013 @default.
- W4300644930 countsByYear W43006449302014 @default.
- W4300644930 countsByYear W43006449302015 @default.
- W4300644930 countsByYear W43006449302016 @default.
- W4300644930 countsByYear W43006449302017 @default.
- W4300644930 countsByYear W43006449302018 @default.
- W4300644930 countsByYear W43006449302019 @default.
- W4300644930 countsByYear W43006449302020 @default.
- W4300644930 countsByYear W43006449302021 @default.
- W4300644930 countsByYear W43006449302022 @default.
- W4300644930 countsByYear W43006449302023 @default.
- W4300644930 crossrefType "journal-article" @default.
- W4300644930 hasAuthorship W4300644930A5048680434 @default.
- W4300644930 hasConcept C126322002 @default.
- W4300644930 hasConcept C140793950 @default.
- W4300644930 hasConcept C168563851 @default.
- W4300644930 hasConcept C19038510 @default.
- W4300644930 hasConcept C2777171753 @default.
- W4300644930 hasConcept C2779946292 @default.
- W4300644930 hasConcept C2909208804 @default.
- W4300644930 hasConcept C44249647 @default.
- W4300644930 hasConcept C505870484 @default.
- W4300644930 hasConcept C535046627 @default.
- W4300644930 hasConcept C543025807 @default.
- W4300644930 hasConcept C55493867 @default.
- W4300644930 hasConcept C71924100 @default.
- W4300644930 hasConcept C84393581 @default.
- W4300644930 hasConcept C86803240 @default.
- W4300644930 hasConceptScore W4300644930C126322002 @default.
- W4300644930 hasConceptScore W4300644930C140793950 @default.
- W4300644930 hasConceptScore W4300644930C168563851 @default.
- W4300644930 hasConceptScore W4300644930C19038510 @default.
- W4300644930 hasConceptScore W4300644930C2777171753 @default.
- W4300644930 hasConceptScore W4300644930C2779946292 @default.
- W4300644930 hasConceptScore W4300644930C2909208804 @default.
- W4300644930 hasConceptScore W4300644930C44249647 @default.
- W4300644930 hasConceptScore W4300644930C505870484 @default.
- W4300644930 hasConceptScore W4300644930C535046627 @default.
- W4300644930 hasConceptScore W4300644930C543025807 @default.
- W4300644930 hasConceptScore W4300644930C55493867 @default.
- W4300644930 hasConceptScore W4300644930C71924100 @default.
- W4300644930 hasConceptScore W4300644930C84393581 @default.
- W4300644930 hasConceptScore W4300644930C86803240 @default.
- W4300644930 hasIssue "12" @default.
- W4300644930 hasLocation W43006449301 @default.
- W4300644930 hasOpenAccess W4300644930 @default.
- W4300644930 hasPrimaryLocation W43006449301 @default.
- W4300644930 hasRelatedWork W1984929305 @default.
- W4300644930 hasRelatedWork W1990478119 @default.
- W4300644930 hasRelatedWork W2029389630 @default.
- W4300644930 hasRelatedWork W2110419883 @default.
- W4300644930 hasRelatedWork W2168330912 @default.
- W4300644930 hasRelatedWork W2735678088 @default.
- W4300644930 hasRelatedWork W2767032596 @default.
- W4300644930 hasRelatedWork W3027083723 @default.
- W4300644930 hasRelatedWork W4240245402 @default.
- W4300644930 hasRelatedWork W4386838227 @default.
- W4300644930 hasVolume "153" @default.
- W4300644930 isParatext "false" @default.
- W4300644930 isRetracted "false" @default.
- W4300644930 workType "article" @default.